The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

There may be trouble on the horizon for the new bloodthinner from Pfizer and Bristol-Myers Squibb. Eliquis, the new bloodthinner, is rumored to be the subject of an upcoming FDA advisory meeting scheduled for May 23rd. Tim Anderson, of Sanford Bernstein, wrote in an investor note that he believed Eliquis would be a topic of discussion at the upcoming meeting.

Concerns about the safety of Pradaxa may be to blame for the FDA’s increased wariness of Eliquis. Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals has been linked to 505 cases of hemorrhaging in the first quarter of 2011. Anderson comments that, “our best guess remains that FDA may be seeking cover, given the safety experience following competing drug Pradaxa’s approval in 2010."

Comments for this article are closed.